Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: IGHG1 upregulation promoted gastric cancer malignancy via AKT/GSK-3β/β-Catenin pathway

Fig. 5

β-Catenin pathway was down-stream target of IGHG1. A Western Blot detection of β-Catenin protein expression on AGS and MKN45 cell groups respectively transfected with IGHG1 specific shRNA and overexpression vectors; B TOPflash/FOPflash detection of β-Catenin transcriptive activity of AGS and MKN45 cell groups respectively transfected with IGHG1 specific shRNA and overexpression vectors; C, D Western Blot and qRT-PCR detection on the expression levels of β-Catenin target genes (Axin 2 and Survivin); E Transwell assay to evaluate the MKN45 cell migration, each cell group was treated by IGHG1 overexpression vector, with or without co-transfection of β-Catenin specific siRNAs; F CCK8 assay to evaluate the proliferation of MKN45 cell groups treated by IGHG1 overexpression vector, with or without co-transfection of β-Catenin specific siRNAs; GI Chemo-resistance evaluation on MKN45 cell groups treated by IGHG1 overexpression vector, with or without co-transfection of β-Catenin specific siRNAs. Cells were respectively treated by escalated dosage of doxorubicin, fluorouracil and cisplatin; J, K qRT-PCR detection of PCNA, CyclinD1, Ncadherin, Vimentin and E-Cadherin mRNA expression level in MKN45 cell groups treated by IGHG1 overexpression vector, with or without co-transfection of β-Catenin specific siRNAs

Back to article page